DGAP-News: iOmx Therapeutics raises EUR 65 million in Series B round
Retrieved on:
Tuesday, October 5, 2021
Apollon, MSD, EUR, VC, Precision medicine, German Cancer Research Center, DGAP, Family, Growth, Wellington Partners, Investment, Artificial intelligence, Volkswagen, Gesellschaft mit beschränkter Haftung, CEO, Science, Boston Scientific, Lead, Machine learning, Supervisory board, Cancer, Neoplasm, Therapy, BioNTech, PD-1, Sofinnova, AZ, J&J, MIG, News, List of life sciences, MD, Ambu, PerkinElmer, Nasdaq, Security (finance), Fine chemical, Vaccine, iOmx Therapeutics, Athos Service GmbH, M Ventures, MIG Capital AG, Sofinnova Partners, Wellington Partners, IOMX THERAPEUTICS, ATHOS SERVICE GMBH, M VENTURES, MIG CAPITAL AG, SOFINNOVA PARTNERS, WELLINGTON PARTNERS
Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders
Key Points:
- Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders
The new funds will be used to advance iOmx' lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology
Martinsried / Munich, Germany, 5 October, 2021 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million. - He added: "We are pleased to join a world-class investor consortium and to begin to work with a highly talented and dedicated team at iOmx".
- Dr. Gerald Moeller, Chairman of iOmx' Supervisory Board commented: "We now have the financial power to dynamically move forward.
- iOmx Therapeutics ( www.iomx.com ) is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells.